查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1691787

視網膜靜脈阻塞治療市場 - 全球產業規模、佔有率、趨勢、機會和預測，按疾病類型、治療方法、最終用戶區域和競爭細分，2020-2030 年預測

Retinal Vein Occlusion Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Disease Type, By Treatment, By End-user Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球視網膜靜脈阻塞治療市場價值為 28.7 億美元，預計到 2030 年將達到 42.6 億美元，預測期內複合年成長率為 6.80%。全球視網膜靜脈阻塞治療市場是更廣泛的醫療保健產業中一個充滿活力且快速發展的產業。視網膜靜脈阻塞 (RVO) 是一種常見的眼部血管疾病，如果不及時治療，會導致視力障礙，因此成為患者和醫療保健專業人員關注的重大問題。隨著全球老年人口不斷成長，RVO 的盛行率不斷上升，推動了對創新有效治療方案的需求。

市場概況
預測期 2026-2030
2024 年市場規模 28.7 億美元
2030 年市場規模 42.6 億美元
2025-2030 年複合年成長率 6.80%
成長最快的領域 視網膜分支靜脈阻塞
最大的市場 北美洲

影響全球 RVO 治療市場的關鍵因素包括醫療技術的進步、患者意識的提高以及研發活動的激增。製藥公司積極致力於開發治療 RVO 的新藥物和療法，重點是改善患者的治療效果和生活品質。 RVO 治療市場涵蓋各種方法，包括藥物介入、雷射治療和外科手術。抗 VEGF（血管內皮生長因子）藥物近年來作為有效的藥物治療選擇而受到廣泛關注，有助於減少 RVO 患者的水腫並改善視力。此外，在特定情況下，還可採用雷射治療和手術介入來控制併發症或恢復受影響的視網膜靜脈的血流。

主要市場促進因素

老齡人口不斷增加

主要市場挑戰

治療選擇有限

主要市場趨勢

藥物治療的進展

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型（視網膜中央靜脈阻塞 (CRVO)、視網膜分支靜脈阻塞 (BRVO)）
    • 依治療（抗血管內皮生長因子 (Anti-VEGF)、皮質類固醇藥物、其他）
    • 按最終用戶（醫院和診所、零售藥局、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖
    • 依疾病類型
    • 按治療
    • 按最終用戶
    • 按地區

第 5 章：亞太地區視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 依疾病類型
    • 按治療
    • 按最終用戶
    • 按國家
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 6 章：歐洲視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 7 章：北美視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 8 章：南美洲視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 9 章：中東和非洲視網膜靜脈阻塞治療市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 10 章：市場動態

  • 驅動程式
  • 挑戰

第 11 章：市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 12 章：全球視網膜靜脈阻塞治療市場：SWOT 分析

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Taiwan Liposome Company, Ltd.
  • Aerie Pharmaceuticals Inc.
  • CalciMedica Inc.
  • Outlook Therapeutics, Inc.
  • Kodiak Sciences Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Pfizer Inc.

第 15 章：策略建議

第16章調查會社について,免責事項

簡介目錄
Product Code: 20743

Global Retinal Vein Occlusion Treatment Market was valued at USD 2.87 billion in 2024 and is expected to reach USD 4.26 billion by 2030 with a CAGR of 6.80% during the forecast period. The global retinal vein occlusion treatment market is a dynamic and rapidly evolving sector within the broader healthcare industry. Retinal vein occlusion (RVO) is a common vascular disorder of the eye that can lead to vision impairment if left untreated, making it a significant concern for both patients and healthcare professionals. As the aging population continues to grow worldwide, the prevalence of RVO is on the rise, driving the demand for innovative and effective treatment options.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.87 Billion
Market Size 2030USD 4.26 Billion
CAGR 2025-20306.80%
Fastest Growing SegmentBranch Retinal Vein Occlusion
Largest MarketNorth America

Key factors influencing the global RVO treatment market include advancements in medical technology, increasing awareness among patients, and a surge in research and development activities. Pharmaceutical companies are actively engaged in the development of novel drugs and therapies to address RVO, with a focus on improving patient outcomes and quality of life. The market for RVO treatment encompasses various approaches, including pharmacological interventions, laser therapy, and surgical procedures. Anti-VEGF (vascular endothelial growth factor) drugs have gained prominence in recent years as an effective pharmacological treatment option, helping to reduce edema and improve vision in RVO patients. Additionally, laser therapy and surgical interventions are utilized in specific cases to manage complications or restore blood flow in the affected retinal veins.

Key Market Drivers

Growing Aging Population

The aging population is a significant factor contributing to the growth of the global retinal vein occlusion (RVO) treatment market. As the world's demographic landscape undergoes a profound shift, with a substantial increase in the elderly population, the incidence of age-related eye conditions, such as RVO, is on the rise. RVO is notably more prevalent in individuals over the age of 50, making it a condition closely associated with the aging process. This demographic shift is driving demand for effective RVO treatments and significantly impacting the market in several ways.

According to WHO, by 2030, 1 in 6 people in the world will be aged 60 years or over. At this time the share of the population aged 60 years and over will increase from 1 billion in 2020 to 1.4 billion. By 2050, the world's population of people aged 60 years and older will double (2.1 billion). The number of persons aged 80 years or older is expected to triple between 2020 and 2050 to reach 426 million.

Key Market Challenges

Limited Treatment Options

The global retinal vein occlusion (RVO) treatment market faces a significant hurdle in the form of limited treatment options, which is hindering its growth and effectiveness. RVO is a vascular eye disorder that can result in vision impairment, and while there have been notable advances in treatment options, there remains a substantial portion of patients for whom the available treatments may be insufficient. This limitation poses a major challenge, as it leaves a significant portion of RVO patients without optimal solutions for their condition.

At present, the primary pharmacological approach to RVO treatment involves anti-vascular endothelial growth factor (anti-VEGF) drugs, which have shown efficacy in addressing macular edema and inflammation. However, these treatments are not universally effective, and there is a considerable variation in patient responses. Some individuals may experience minimal or no improvement, while others may require ongoing treatment that can be burdensome and uncomfortable. The inability to offer personalized, effective treatment options for all RVO patients hinders the market's ability to meet the diverse needs of

Key Market Trends

Advancements in Pharmacological Treatments

Advancements in pharmacological treatments have played a pivotal role in boosting the global retinal vein occlusion (RVO) treatment market. RVO, a vascular eye disorder that can lead to vision impairment, has seen remarkable progress in the development of novel therapies, particularly in the form of anti-vascular endothelial growth factor (anti-VEGF) drugs. These advancements have significantly improved the landscape of RVO treatment, offering patients more effective and convenient options for managing the condition.

Anti-VEGF drugs, such as aflibercept and ranibizumab, have emerged as the cornerstone of RVO treatment, primarily addressing RVO-related macular edema. These drugs work by inhibiting the growth of abnormal blood vessels in the retina, reducing inflammation, and preventing the leakage of fluid into the macula. The introduction of anti-VEGF treatments has revolutionized RVO management, offering patients a less invasive and more patient-friendly therapeutic approach. They have proven effective in reducing edema, improving visual outcomes, and preserving the patient's quality of life.

Key Market Players

  • AbbVie Inc.
  • F. Hoffmann-La Roche Ltd.
  • Regeneron Pharmaceuticals Inc.
  • Taiwan Liposome Company, Ltd.
  • Aerie Pharmaceuticals Inc.
  • CalciMedica Inc.
  • Outlook Therapeutics, Inc.
  • Kodiak Sciences Inc.
  • Chugai Pharmaceutical Co., Ltd.
  • Pfizer Inc.

Report Scope:

In this report, the Global Retinal Vein Occlusion Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Retinal Vein Occlusion Treatment Market, By Disease Type:

  • Central Retinal Vein Occlusion (CRVO)
  • Branch Retinal Vein Occlusion (BRVO)

Retinal Vein Occlusion Treatment Market, By Treatment:

  • Anti-vascular Endothelial Growth Factor (Anti-VEGF)
  • Corticosteroid Drugs
  • Others

Retinal Vein Occlusion Treatment Market, By End-user:

  • Fully Automated
  • Semi-Automated
  • Manual

Retinal Vein Occlusion Treatment Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Retinal Vein Occlusion Treatment Market.

Available Customizations:

Global Retinal Vein Occlusion Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Retinal Vein Occlusion Treatment Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Disease Type (Central Retinal Vein Occlusion (CRVO), Branch Retinal Vein Occlusion (BRVO))
    • 4.2.2. By Treatment (Anti-vascular Endothelial Growth Factor (Anti-VEGF), Corticosteroid Drugs, Others)
    • 4.2.3. By End-user (Hospital & Clinics, Retail Pharmacy, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2024)
  • 4.3. Market Map
    • 4.3.1. By Disease Type
    • 4.3.2. By Treatment
    • 4.3.3. By End-user
    • 4.3.4. By Region

5. Asia Pacific Retinal Vein Occlusion Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Disease Type
    • 5.2.2. By Treatment
    • 5.2.3. By End-user
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Retinal Vein Occlusion Treatment Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Disease Type
        • 5.3.1.2.2. By Treatment
        • 5.3.1.2.3. By End-user
    • 5.3.2. India Retinal Vein Occlusion Treatment Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Disease Type
        • 5.3.2.2.2. By Treatment
        • 5.3.2.2.3. By End-user
    • 5.3.3. Australia Retinal Vein Occlusion Treatment Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Disease Type
        • 5.3.3.2.2. By Treatment
        • 5.3.3.2.3. By End-user
    • 5.3.4. Japan Retinal Vein Occlusion Treatment Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Disease Type
        • 5.3.4.2.2. By Treatment
        • 5.3.4.2.3. By End-user
    • 5.3.5. South Korea Retinal Vein Occlusion Treatment Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Disease Type
        • 5.3.5.2.2. By Treatment
        • 5.3.5.2.3. By End-user

6. Europe Retinal Vein Occlusion Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Disease Type
    • 6.2.2. By Treatment
    • 6.2.3. By End-user
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Retinal Vein Occlusion Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Disease Type
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By End-user
    • 6.3.2. Germany Retinal Vein Occlusion Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Disease Type
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By End-user
    • 6.3.3. Spain Retinal Vein Occlusion Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Disease Type
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By End-user
    • 6.3.4. Italy Retinal Vein Occlusion Treatment Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Disease Type
        • 6.3.4.2.2. By Treatment
        • 6.3.4.2.3. By End-user
    • 6.3.5. United Kingdom Retinal Vein Occlusion Treatment Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Disease Type
        • 6.3.5.2.2. By Treatment
        • 6.3.5.2.3. By End-user

7. North America Retinal Vein Occlusion Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Disease Type
    • 7.2.2. By Treatment
    • 7.2.3. By End-user
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Retinal Vein Occlusion Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Disease Type
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By End-user
    • 7.3.2. Mexico Retinal Vein Occlusion Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Disease Type
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By End-user
    • 7.3.3. Canada Retinal Vein Occlusion Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Disease Type
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By End-user

8. South America Retinal Vein Occlusion Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Disease Type
    • 8.2.2. By Treatment
    • 8.2.3. By End-user
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Retinal Vein Occlusion Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Disease Type
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By End-user
    • 8.3.2. Argentina Retinal Vein Occlusion Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Disease Type
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By End-user
    • 8.3.3. Colombia Retinal Vein Occlusion Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Disease Type
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By End-user

9. Middle East and Africa Retinal Vein Occlusion Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Disease Type
    • 9.2.2. By Treatment
    • 9.2.3. By End-user
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Retinal Vein Occlusion Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Disease Type
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By End-user
    • 9.3.2. Saudi Arabia Retinal Vein Occlusion Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Disease Type
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By End-user
    • 9.3.3. UAE Retinal Vein Occlusion Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Disease Type
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By End-user

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Retinal Vein Occlusion Treatment Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. AbbVie Inc.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Regeneron Pharmaceuticals Inc.
  • 14.4. Taiwan Liposome Company, Ltd.
  • 14.5. Aerie Pharmaceuticals Inc.
  • 14.6. CalciMedica Inc.
  • 14.7. Outlook Therapeutics, Inc.
  • 14.8. Kodiak Sciences Inc.
  • 14.9. Chugai Pharmaceutical Co., Ltd.
  • 14.10.Pfizer Inc.

15. Strategic Recommendations

16. About Us & Disclaimer